| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Dabrafeib |
| Brand | Tafinlar® |
| Indication | For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
| Assessment Process | |
| Rapid review commissioned | 11/09/2013 |
| Rapid review completed | 02/10/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 03/12/2013 |
| NCPE assessment completed | 24/06/2014 |
| NCPE assessment outcome | The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib. |
